FANCA: Difference between revisions
CSV import |
CSV import |
||
| Line 25: | Line 25: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 11:35, 17 March 2025
| Symbol | – |
|---|---|
| HGNC ID | – |
| Alternative symbols | – |
| Entrez Gene | – |
| OMIM | – |
| RefSeq | – |
| UniProt | – |
| Chromosome | – |
| Locus supplementary data | – |
FANCA is a gene that encodes a protein crucial for the cellular response to DNA damage, specifically involved in the repair of DNA interstrand crosslinks. This gene plays a significant role in maintaining the stability of the cell's genetic material and is part of a larger group of genes associated with Fanconi anemia (FA), a rare genetic disorder that leads to bone marrow failure and increased cancer risk.
Function[edit]
The FANCA protein is part of the core complex of the FA pathway, which is responsible for the activation of the FA/BRCA (BRCA1 and BRCA2) DNA repair pathway. When DNA damage is detected, the FA core complex activates the FANCD2 and FANCI proteins by monoubiquitination, a critical step in the repair process. This activation allows for the recruitment of other DNA repair proteins to the site of damage, facilitating the repair of DNA crosslinks and thus ensuring genomic stability.
Genetic Location[edit]
FANCA is located on chromosome 16 (16q24.3) in humans. It consists of 43 exons, and mutations in this gene are the most common cause of Fanconi anemia, accounting for 60-70% of all cases.
Clinical Significance[edit]
Mutations in the FANCA gene lead to Fanconi anemia, a condition characterized by bone marrow failure, congenital abnormalities, and an increased risk of developing cancers such as acute myeloid leukemia (AML) and squamous cell carcinomas. Patients with Fanconi anemia typically present with physical abnormalities, bone marrow failure, and cellular hypersensitivity to DNA crosslinking agents, which are used as a diagnostic test for FA.
Diagnosis and Treatment[edit]
Diagnosis of Fanconi anemia involves chromosomal breakage analysis using diepoxybutane (DEB) or mitomycin C (MMC), which can induce DNA crosslinks and reveal characteristic chromosomal abnormalities in FA patients. Genetic testing for mutations in FANCA and other FA genes is also performed to confirm the diagnosis.
Treatment options for Fanconi anemia include androgen therapy, growth factors, and bone marrow transplantation. Gene therapy is also being explored as a potential treatment to correct the genetic defect in hematopoietic stem cells.
Research[edit]
Ongoing research on FANCA and the FA pathway focuses on understanding the detailed mechanisms of DNA repair and how mutations in these genes lead to the clinical manifestations of Fanconi anemia. This research is crucial for developing more effective treatments and potentially preventive strategies for those affected by this condition.
